Moderna’s mRNA Flu Vaccine Wins Unanimous FDA Panel Backing
Strategic News Watch — June 19, 2026
|
An FDA advisory panel handed Moderna a unanimous 9-0 endorsement for its mRNA flu vaccine — reversing the agency’s earlier refusal to review it — as AbbVie closed in on an $11 billion takeover of Apogee Therapeutics and Washington opened a trade probe into German drug pricing.
Today’s top developments:
|
What to Watch
- Moderna mRNA-1010 FDA Decision: With the advisory panel’s unanimous backing, attention turns to the FDA’s action date of August 5, 2026 — and whether the 65-and-older indication clears as an accelerated approval tied to the planned confirmatory trial.
- AbbVie–Apogee Announcement: A formal deal could land as early as Monday, June 22, 2026; watch for confirmed terms, the immunology assets gained, and any rival bid given the reported ~60% premium.
- German Drug-Pricing Probe: The Section 301 comment window runs June 25 to August 10, 2026, with a September 22, 2026 hearing — escalation could test the 15% pharma tariff cap in the US-EU trade deal.
- 340B Program Tensions: Lilly’s discount eliminations may embolden other manufacturers to impose similar data requirements, potentially reshaping the 340B landscape and triggering legislative or regulatory responses.
- FDA Voucher Program Reevaluation: Calls to pause the Commissioner’s National Priority Review Voucher program could prompt added transparency requirements or a rethink of how expedited-review candidates are selected.
This brief highlights the edition’s top stories. Read the latest edition → for all stories and analysis.
